Table 2 The tumor volume with anti-CD25 and/or anti-TGF-β treatment in different periods
Cohorts | Number | Day 7 (p value) | Day 14 (p value) | Day 21 (p value) | Day 28 (p value) | Day 35 (p value) |
|---|---|---|---|---|---|---|
Control | 5 | 9.92 ± 5.82 (1) | 38.30 ± 29.00 (1) | 259.43 ± 171.47 (1) | 942.92 ± 745.58 (1) | 1962.19 ± 1326.31 (1) |
Anti-TGF-β | 5 | 5.19 ± 4.00 (0.142) | 14.60 ± 9.08 (0.056) | 63.57 ± 40.38 (0.053) | 487.30 ± 530.90 (0.353) | 984.64 ± 719.09 (0.211) |
Anti-CD25 | 5 | 2.22 ± 2.90 (0.012) | 3.97 ± 4.28 (0.005) | 90.74 ± 123.26 (0.104) | 257.59 ± 310.82 (0.104) | 774.40 ± 867.07 (0.108) |
Anti-TGF-β+ anti-CD25 | 6 | 0.01 ± 0.004 (0.001) | 0.46 ± 0.85 (0.002) | 48.31 ± 115.88 (0.028) | 120.39 ± 288.12 (0.035) | 160.81 ± 347.21 (0.008) |